BSE filing, NSE: MUTHOOTMF. Summary written from the filing by ALFA Finder's alert engine.
Muthoot Microfin Ltd: key numbers
- Share price
- ₹140.00
- Market cap
- ₹2,387 Cr
- Revenue (annual)
- ₹2,370 Cr
- Net profit (annual)
- ₹170.3 Cr
- P/E (TTM)
- 9.7×Sector 19.7×
- Promoter holding
- 55.47%+0.00% QoQ
- FII holding
- 23.19%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Muthoot Microfin Ltd
All →Muthoot Microfin Credit Rating
CareEdge reaffirmed Muthoot Microfin's long-term foreign currency rating at BB- and revised the outlook to Positive from Stable. The move reflects improving asset quality and profitability.
Muthoot Microfin Board Meeting Date
Muthoot Microfin will hold a board meeting on 5 Nov 2026 to consider Q1 FY27 unaudited standalone financial results and other business. The trading window remains closed until 7 Nov 2026.
Muthoot Microfin Business Update
Muthoot Microfin reported its Q2 FY27 key business update, highlighting an AUM of Rs. 15,323 Crore and disbursements of Rs. 2,900 Crore.
Muthoot Microfin Debt & Borrowing
Muthoot Microfin Limited submitted its half-yearly statement of outstanding debt securities and commercial papers for the period ended September 30, 2026. The report lists active ISINs.
Muthoot Microfin Other Announcement
The company submitted compliance confirmations for Regulation 6(1) regarding the Compliance Officer and Regulation 7(1) regarding the Share Transfer Agent for the quarter ended September 2026.
Muthoot Microfin Other Announcement
Muthoot Microfin filed its monthly ALM statement for August 2026 as required by SEBI. The filing is a routine compliance report with no new business transaction.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.